Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
- R. Esser, T. Müller, W. Wels
- Biology, MedicineJournal of cellular and molecular medicine
- 28 February 2012
Clonal derivatives of the clinically applicable human NK cell line NK‐92 are generated that stably express a GD2‐specific chimeric antigen receptor (CAR) comprising an anti‐GD2 ch14.18 single chain Fv antibody fusion protein with CD3‐ζ chain as a signalling moiety to combine specific antibody‐mediated recognition of NB cells with the potent cytotoxic activity of NK cells.
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
LTI of ch14.18/CHO induced effector mechanisms over the entire treatment period, and may therefore emerge as the preferred delivery method of anti-GD2 immunotherapy to NB patients.
Impedimetric real-time monitoring of neural pluripotent stem cell differentiation process on microelectrode arrays.
Induced Tauopathy in a Novel 3D-Culture Model Mediates Neurodegenerative Processes: A Real-Time Study on Biochips
A novel 3D SH-SY5Y cell-based, tauopathy model that shows advanced characteristics of matured neurons in comparison to monolayer cultures without the need of artificial differentiation promoting agents and quantify a time- and concentration-dependent relative impedance decrease when Alzheimer’s disease-like tau pathology was induced in the neuronal 3D cell culture model.
Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice
Proof of concept that MYCN can be targeted by DNA vaccination is demonstrated, which may provide an approach to overcoming MYCN immune-suppressive activities in patients with MYCN-amplified disease.
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
- N. Siebert, D. Seidel, Christin Eger, Madlen Jüttner, H. Lode
- Biology, MedicinePloS one
- 16 September 2014
Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option…
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
The induction of a GD2-specific immune response with ganglidiomab, a new anti-idiotype antibody to anti-GD2 antibodies of the 14.18 family is reported, proving GD2 surrogate function and anti-IDiotype characteristics and demonstrating activity against neuroblastoma.
A Novel 3D Label-Free Monitoring System of hES-Derived Cardiomyocyte Clusters: A Step Forward to In Vitro Cardiotoxicity Testing
A microcavity array (MCA)-based label-free monitoring system that eliminates the need for critical hCMC adhesion and outgrowth steps and gives a comprehensive insight into induced cellular alterations within a complex cardiac culture over days or even weeks.
A novel 384-multiwell microelectrode array for the impedimetric monitoring of Tau protein induced neurodegenerative processes.